Mert, A. Et Al. 2022. Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. RHEUMATOLOGY INTERNATIONAL , vol.42, no.3 , 457-467.

Mert, A., Vahaboğlu, H., Arslan, F., Batirel, A., Saracoglu, K. T., Bastug, A., ... Cagatay, A.(2022). Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. RHEUMATOLOGY INTERNATIONAL , vol.42, no.3, 457-467.

Mert, Ali Et Al. "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls," RHEUMATOLOGY INTERNATIONAL , vol.42, no.3, 457-467, 2022

Mert, Ali Et Al. "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls." RHEUMATOLOGY INTERNATIONAL , vol.42, no.3, pp.457-467, 2022

Mert, A. Et Al. (2022) . "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls." RHEUMATOLOGY INTERNATIONAL , vol.42, no.3, pp.457-467.

@article{article, author={Ali Mert Et Al. }, title={Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls}, journal={RHEUMATOLOGY INTERNATIONAL}, year=2022, pages={457-467} }